Survival Analysis in HTA Submissions: A Primer

Life Sciences, Clinical Trials, Commercialization & HEOR,
  • Friday, May 15, 2020 | 11am EDT (NA) / 4pm BST (UK) / 5pm CEST (EU-Central)
  • 60 min

Economic evaluations for health technology assessments (HTAs) often rely on estimates of “time-to-event” for patient outcomes, such as time to disease progression, time to first stroke, or time to death to assess the costs and benefits of a treatment or intervention.

Analysis of time-to-event data – also known as survival analysis – can provide estimates of survivor functions and event rates that inform these economic analyses. As well as characterising event rates over an observed period of time, such as the duration of a clinical trial, survival analysis techniques are used to extrapolate the results over a lifetime to generate estimates of mean survival benefit.

Estimates of an intervention’s cost-effectiveness can be sensitive to the methods applied in modelling and extrapolating survival data. Typically, these projections are performed using various parametric models, with each model making different assumptions about the underlying hazard function. Advanced techniques have recently been developed to account for complex challenges such as interval censoring, cured patients and treatment crossover.

Join this free webinar in which the basics of survival analysis will be reviewed and how it can be used in economic evaluations.

Speakers

Victoria Paly, MHS, Principal, Global Health Economics, ICON

Victoria Paly has worked in health economics and outcomes research for over ten years supporting the development of effective value propositions for pharmaceutical products. She has extensive experience in survival analysis and economic modelling, including development of cost-effectiveness analyses to support HTA submissions.

Message Presenter
http://Dhvani%20Shah,%20ICON

Dhvani Shah, MS, Principal, Global Health Economics, ICON

Dhvani Shah has over ten years of experience in health economics and outcomes research and has led numerous evidence generation activities to demonstrate and communicate product value. At ICON, she is responsible for preparing HEOR research and value strategies, developing economic models for HTA submissions and conducting evidence synthesis activities.

Message Presenter

Who Should Attend?

This program is intended for professionals from pharmaceutical, biotech and medical device companies involved in:

  • Health economics & outcomes research (HEOR)
  • Marketing
  • Market access
  • Medical affairs
  • Regulatory affairs
  • Pharmacovigilance and risk management

 

What You Will Learn

In this webinar, attendees will learn about:

  • Current guidelines on extrapolating time-to-event data from clinical trials
  • Challenges when conducting survival analysis on immature data
  • Recent developments in the field of survival analysis

 

Xtalks Partner

ICON

ICON plc is a global provider of outsourced development and commercialization services to pharmaceutical, biotechnology, medical device and government and public health organisations. The company specializes in the strategic development, management and analysis of programs that support clinical development. With headquarters in Dublin, Ireland, ICON currently operates from 98 locations in 40 countries and has approximately 15,100 employees. Further information is available at ICONplc.com.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account